CX-904

N/A

Report date: 2026/03/19 17:03:27

Base Information

Drug NameCX-904
Drug Alias NameCX-904
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT cell surface glycoprotein CD3 inhibitorsT lymphocytes stimulants +[4] 
TargetsEpidermal growth factor receptor erbB1T cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen IncCytomx Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCytomx Therapeutics IncAmgen Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A